These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1005 related articles for article (PubMed ID: 25727967)

  • 61. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A
    Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The safety of new drug treatments for idiopathic pulmonary fibrosis.
    Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
    Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 65. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
    Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
    Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
    Jo HE; Randhawa S; Corte TJ; Moodley Y
    Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
    Selvaggio AS; Noble PW
    Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
    Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
    Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis.
    King CS; Nathan SD
    Curr Opin Pulm Med; 2015 Sep; 21(5):479-89. PubMed ID: 26164298
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
    Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ
    Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options.
    Trachalaki A; Irfan M; Wells AU
    Expert Opin Pharmacother; 2021 Feb; 22(2):191-204. PubMed ID: 32993388
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis.
    Skurikhin E; Nebolsin V; Widera D; Ermakova N; Pershina O; Pakhomova A; Krupin V; Pan E; Zhukova M; Novikov F; Sandrikina L; Morozov S; Kubatiev A; Dygai A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171668
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
    Ballester B; Milara J; Cortijo J
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study.
    Bennett D; Refini RM; Valentini ML; Fui A; Fossi A; Pieroni M; Mazzei MA; Rottoli P
    Lung; 2019 Apr; 197(2):147-153. PubMed ID: 30758708
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis.
    Covvey JR; Mancl EE
    Ann Pharmacother; 2014 Dec; 48(12):1611-9. PubMed ID: 25202034
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
    Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
    Yu W; Guo F; Song X
    Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.